EP2685825A4 - IMADAZAPYRINIDIN-5 (6H) -ESONS SUBSTITUTED AS ALLOSTERIC MODULATORS OF MGLUR5 RECEPTORS - Google Patents

IMADAZAPYRINIDIN-5 (6H) -ESONS SUBSTITUTED AS ALLOSTERIC MODULATORS OF MGLUR5 RECEPTORS

Info

Publication number
EP2685825A4
EP2685825A4 EP12757940.7A EP12757940A EP2685825A4 EP 2685825 A4 EP2685825 A4 EP 2685825A4 EP 12757940 A EP12757940 A EP 12757940A EP 2685825 A4 EP2685825 A4 EP 2685825A4
Authority
EP
European Patent Office
Prior art keywords
imadazapyrinidin
esons
substituted
allosteric modulators
mglur5 receptors
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Withdrawn
Application number
EP12757940.7A
Other languages
German (de)
French (fr)
Other versions
EP2685825A1 (en
Inventor
P Jeffrey Conn
Craig W Linsley
Shaun R Stauffer
Jose Manuel Bartolome-Nebreda
Gregor James Macdonald
Susana Conde-Ceide
Carrie K Jones
Maria Luz Martin-Martin
Han Min Tong
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Vanderbilt University
Original Assignee
Vanderbilt University
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Vanderbilt University filed Critical Vanderbilt University
Publication of EP2685825A1 publication Critical patent/EP2685825A1/en
Publication of EP2685825A4 publication Critical patent/EP2685825A4/en
Withdrawn legal-status Critical Current

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D487/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00
    • C07D487/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00 in which the condensed system contains two hetero rings
    • C07D487/04—Ortho-condensed systems
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/04—Centrally acting analgesics, e.g. opioids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/06—Antimigraine agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/08—Antiepileptics; Anticonvulsants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/18—Antipsychotics, i.e. neuroleptics; Drugs for mania or schizophrenia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/20—Hypnotics; Sedatives
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/22—Anxiolytics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/24—Antidepressants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/30—Drugs for disorders of the nervous system for treating abuse or dependence
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/04—Anorexiants; Antiobesity agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
    • A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A61P35/02—Antineoplastic agents specific for leukemia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • Veterinary Medicine (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Engineering & Computer Science (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Neurology (AREA)
  • Neurosurgery (AREA)
  • Biomedical Technology (AREA)
  • Pain & Pain Management (AREA)
  • Diabetes (AREA)
  • Psychiatry (AREA)
  • Hematology (AREA)
  • Obesity (AREA)
  • Emergency Medicine (AREA)
  • Endocrinology (AREA)
  • Anesthesiology (AREA)
  • Hospice & Palliative Care (AREA)
  • Oncology (AREA)
  • Psychology (AREA)
  • Addiction (AREA)
  • Child & Adolescent Psychology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)
EP12757940.7A 2011-03-15 2012-03-14 IMADAZAPYRINIDIN-5 (6H) -ESONS SUBSTITUTED AS ALLOSTERIC MODULATORS OF MGLUR5 RECEPTORS Withdrawn EP2685825A4 (en)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US201161452921P 2011-03-15 2011-03-15
PCT/US2012/029085 WO2012125732A1 (en) 2011-03-15 2012-03-14 Substituted imadazapyrinidin-5(6h)-ones as allosteric modulators of mglur5 receptors

Publications (2)

Publication Number Publication Date
EP2685825A1 EP2685825A1 (en) 2014-01-22
EP2685825A4 true EP2685825A4 (en) 2014-09-10

Family

ID=46831091

Family Applications (1)

Application Number Title Priority Date Filing Date
EP12757940.7A Withdrawn EP2685825A4 (en) 2011-03-15 2012-03-14 IMADAZAPYRINIDIN-5 (6H) -ESONS SUBSTITUTED AS ALLOSTERIC MODULATORS OF MGLUR5 RECEPTORS

Country Status (5)

Country Link
EP (1) EP2685825A4 (en)
JP (1) JP2014508172A (en)
AU (1) AU2012229983A1 (en)
CA (1) CA2830220A1 (en)
WO (1) WO2012125732A1 (en)

Families Citing this family (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US8703946B2 (en) 2010-12-08 2014-04-22 Vanderbilt University Substituted pyrazolo[1,5-A]pyrazine compounds as allosteric modulators of mGluR5 receptors
US8865725B2 (en) * 2011-03-15 2014-10-21 Vanderbilt University Substituted imidazopyrimidin-5(6H)-ones as allosteric modulators of MGLUR5 receptors
EP2864331B1 (en) * 2012-06-21 2017-08-09 Bristol-Myers Squibb Company Positive allosteric modulators of mglur2
TWI713497B (en) * 2015-02-26 2020-12-21 南韓商愛思開生物製藥股份有限公司 Imidazopyrimidine and imidazotriazine derivative, and pharmaceutical composition comprising the same
KR20220087474A (en) * 2019-10-21 2022-06-24 에스케이바이오팜 주식회사 Use of an imidazopyrimidine or imidazotriazine compound for the prevention, alleviation or treatment of cognitive impairment or for improving cognitive function
CA3155013A1 (en) * 2019-10-21 2021-04-29 Ki Ho Lee Use of imidazopyrimidine or imidazotriazine compound for prevention, alleviation, or treatment of developmental disability
WO2023064223A1 (en) 2021-10-11 2023-04-20 Gossamer Bio Services, Inc. Tri-substituted pyridines

Citations (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2007034282A2 (en) * 2005-09-19 2007-03-29 Pfizer Products Inc. Diaryl-imidazole compounds condensed with a heterocycle as c3a receptor antagonists
WO2008107418A1 (en) * 2007-03-05 2008-09-12 Novartis Ag Fused pyrimidinone compounds as mglur ligands
WO2012083224A1 (en) * 2010-12-17 2012-06-21 Vanderbilt University Bicyclic triazole and pyrazole lactams as allosteric modulators of mglur5 receptors

Family Cites Families (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB8334210D0 (en) * 1983-12-22 1984-02-01 Roussel Lab Ltd Imidazo(1 2-c)pyrimidines
JPH01203366A (en) * 1988-02-10 1989-08-16 Mitsui Petrochem Ind Ltd N-substituted imidazole derivative
TW200823215A (en) * 2006-08-04 2008-06-01 Merz Pharma Gmbh & Amp Co Kgaa Pyrazolopyrimidines, a process for their preparation and the use as a medicine
US20080146523A1 (en) * 2006-12-18 2008-06-19 Guido Galley Imidazole derivatives
US8034806B2 (en) * 2007-11-02 2011-10-11 Vanderbilt University Bicyclic mGluR5 positive allosteric modulators and methods of making and using same

Patent Citations (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2007034282A2 (en) * 2005-09-19 2007-03-29 Pfizer Products Inc. Diaryl-imidazole compounds condensed with a heterocycle as c3a receptor antagonists
WO2008107418A1 (en) * 2007-03-05 2008-09-12 Novartis Ag Fused pyrimidinone compounds as mglur ligands
WO2012083224A1 (en) * 2010-12-17 2012-06-21 Vanderbilt University Bicyclic triazole and pyrazole lactams as allosteric modulators of mglur5 receptors

Non-Patent Citations (1)

* Cited by examiner, † Cited by third party
Title
See also references of WO2012125732A1 *

Also Published As

Publication number Publication date
JP2014508172A (en) 2014-04-03
EP2685825A1 (en) 2014-01-22
WO2012125732A1 (en) 2012-09-20
WO2012125732A8 (en) 2013-10-17
CA2830220A1 (en) 2012-09-20
AU2012229983A1 (en) 2013-10-03

Similar Documents

Publication Publication Date Title
EP2675909A4 (en) COMPOSITION OF GLUCOSYLSTEVIA
EP2720561A4 (en) COMPOSITION OF STÉVIA
EP2736491A4 (en) COMPOSITIONS OF BEPOSTATIN
EP2713762A4 (en) COMPOSITION OF STÉVIA
CO6862108A2 (en) Stabilized formulations containing anti-pcsk9 antibodies
EP2683693A4 (en) INHIBITORS OF RORGAMMAT
EP2693175A4 (en) BALANCE OF COMBINATION
EP2831069A4 (en) INHIBITORS OF beta-LACTAMASES DERIVED FROM ISOXAZOLE
HRP20180809T1 (en) INHIBITIVE COMPOUNDS OF METALOENZYMES
EP2718293A4 (en) SUBSTITUTED PYRIDOPYRAZINES AS NEW SYK INHIBITORS
BR112014003878A2 (en) synthesis of r-biphenylalaninol
EP2713824A4 (en) ENHANCED COMPATIBILITY FOR LIAISON MECHANISM
CO6900143A2 (en) Ethynyl derivatives as allosteric modulators of mglur5
DK3494993T3 (en) NEW USE OF MALTOTRIOSYL TRANSFERASE
EP2683306A4 (en) SLEEVE FOR REMOVABLE LANCETTE OF AUTOPIQUEUR
PL2772482T3 (en) DERIVATIVE OF AZOLE
EP2608672A4 (en) AMINOPYRIDINECARBOXAMIDES AND AMINOPYRIMIDINECARBOXAMIDES FOR USE AS MODULATORS OF CXCR2 RECEPTORS
EP2863912A4 (en) SUBSTITUTED ALCOXY BICYCLIC PYRAZOLE ANALOGUES AS ALLUSTERIC MODULATORS OF MGLUR5 RECEPTORS
EP2725031A4 (en) DERIVATIVES OF C-GLYCOSIDES
EP2707101A4 (en) REGULATORS OF PROTESTOSTASY
EP2648723A4 (en) USE OF BICYCLIC PYRAZOLE COMPOUNDS AS ALLUSTERIC MODULATORS OF MGLUR5 RECEPTORS
PL2720701T3 (en) THERAPEUTIC NON-GELLING APPLICATION OF KRILL OIL
EP2776564A4 (en) MODULATION OF TMPRSS6 EXPRESSION
BR112014007641A2 (en) use of a biocide
DK2817299T3 (en) Substituted chroman compounds as modulators of calcium-detecting receptors

Legal Events

Date Code Title Description
PUAI Public reference made under article 153(3) epc to a published international application that has entered the european phase

Free format text: ORIGINAL CODE: 0009012

17P Request for examination filed

Effective date: 20131010

AK Designated contracting states

Kind code of ref document: A1

Designated state(s): AL AT BE BG CH CY CZ DE DK EE ES FI FR GB GR HR HU IE IS IT LI LT LU LV MC MK MT NL NO PL PT RO RS SE SI SK SM TR

AX Request for extension of the european patent

Extension state: BA ME

A4 Supplementary search report drawn up and despatched

Effective date: 20140811

RIC1 Information provided on ipc code assigned before grant

Ipc: A61K 31/519 20060101AFI20140805BHEP

Ipc: A61P 25/00 20060101ALI20140805BHEP

STAA Information on the status of an ep patent application or granted ep patent

Free format text: STATUS: THE APPLICATION IS DEEMED TO BE WITHDRAWN

18D Application deemed to be withdrawn

Effective date: 20150310